February 20, 2017
Cambridge, MA — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced today that Peter G. Smith, Ph.D., will become the company’s chief scientific officer, effective March 1, 2017. Dr. Smith transitions to his new position from vice president, Drug Discovery Biology.
“Since joining H3 shortly after the company’s inception, Pete has been essential to the rapid success of the company and a driving force behind our pre-clinical and clinical advancements,” said Dr. Markus Warmuth, president and CEO of H3 Biomedicine. “Under Pete’s scientific leadership, H3 brought forward its first two oncology drug candidates and established a robust pre-clinical program that shows enormous promise.”
In his role as chief scientific officer, Dr. Smith will be responsible for setting the scientific strategy and priorities for H3 Biomedicine, as well as overseeing day-to-day research operations.
“I am grateful for this recognition of my contributions to H3, and am honored to be part of such a transformative company,” said Dr. Smith. “It has been a privilege to help H3 advance from a young, discovery-stage company to one with a strong clinical footprint and the potential to grow that even further over the next few years.”
Dr. Smith joined H3 Biomedicine in 2011 as the director of Target Biology, and soon advanced to the position of vice president, Drug Discovery Biology. Within this capacity, he led a multidisciplinary team of scientists towards the identification and early development of novel small molecule oncology therapeutics. Under Dr. Smith’s leadership, H3’s scientific team has delivered two clinical stage compounds (H3B-8800 and H3B-6527), and a third pre-clinical compound which is scheduled for clinical introduction in Q2 2017. Dr. Smith came to H3 Biomedicine from Millennium Pharmaceuticals/Takeda Oncology in Cambridge, Mass., where he held positions of increasing scientific and management responsibility in the oncology discovery group.
Prior to Millennium, Dr. Smith served as a post-doctoral researcher at the Dana-Farber Cancer Institute, Harvard Medical School; at the Molecular Medicine Unit, St James’s University Hospital, University of Leeds, U.K.; and at the Cancer Research Unit, University of Newcastle upon Tyne, U.K. Dr. Smith earned a Ph.D. from the Cancer Research Unit at the University of Newcastle upon Tyne, U.K. and a B.Sc. in pharmacology from the University of Sheffield, U.K.
About H3 Biomedicine Inc.
H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, which was established as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.